| Literature DB >> 34108438 |
Michelle Ho1,2, Beau Y Park3, Norman G Rosenblum3, Mona Al Mukaddam4, Frederick S Kaplan4, Victor Kucherov5, Scott G Hubosky5, Gregory Kane6, Vishal Desai7, Michael R Kramer7, Bon S Ku2,8, Eric S Schwenk9, Jaime L Baratta9, Deepti Harshavardhana9, Zvi Grunwald9.
Abstract
BACKGROUND Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disorder of the connective tissue. Over time, patients with FOP experience decreased range of motion in the joints and the formation of a second skeleton, limiting mobility. Patients with FOP are advised to avoid any unwarranted surgery owing to the risk of a heterotopic ossification flare-up. For patients who do require a surgical procedure, a multidisciplinary team is recommended for comprehensive management of the patient's needs. CASE REPORT A 27-year-old woman with FOP underwent a hysterectomy for removal of a suspected necrotic uterine fibroid. To aid in presurgical planning and management, patient-specific 3-dimensional (3D) models of the patient's tracheobronchial tree, thorax, and lumbosacral spine were printed from the patient's preoperative computed tomography (CT) imaging. The patient required awake nasal fiberoptic intubation for general anesthesia and transversus abdominus plane block for regional anesthesia. Other anesthesia modalities, including spinal epidural, were ruled out after visualizing the patient's anatomy using the 3D model. Postoperatively, the patient was started on a multi-modal analgesic regimen and a course of steroids, and early ambulation was encouraged. CONCLUSIONS Patients with FOP are high-risk surgical patients requiring the care of multiple specialties. Advanced visualization methods, including 3D printing, can be used to better understand their anatomy and locations of heterotopic bone ossification that can affect patient positioning. Our patient successfully underwent supracervical hysterectomy and bilateral salpingectomy with no signs of fever or sepsis at follow-up.Entities:
Mesh:
Year: 2021 PMID: 34108438 PMCID: PMC8207543 DOI: 10.12659/AJCR.931614
Source DB: PubMed Journal: Am J Case Rep ISSN: 1941-5923
Pulmonary function data.
| FVC (L) | 2.20 | 1.85 | −16 |
| FVC %Pred | 54 | 46 | |
| FEV1 (L) | 1.99 | 1.72 | −13 |
| FEV1 %Pred | 57 | 50 | |
| FEV1/FVC (%) | 90 | 93 | +3 |
| FEF25%–75% (L/s) | 2.58 | 2.06 | −20 |
| FEF25%–75% %Pred | 69 | 56 |
FVC – forced vital capacity; L – liter;%Pred – % of predicted value; FEV1 – forced exhaled volume in first second; FEF 25%–75% – forced expiratory flow over the middle one half of the FVC.
Perioperative medications.
| Analgesia | 1000 mg acetaminophen, 200 mg celecoxib, 75 mgpregabalin | 15 mL ropivacaine (bilateral TAP block) | |||
| Antibiotic | 500 mg metronidazole, 2000 mg cefazolin | 500 mg metronidazole, 2000 mg cefazolin | |||
| Flare-ups | 80 mg methylprednisolone | 100 mg prednisone | 100 mg prednisone | 100 mg prednisone |
POD – postoperative day.